September is observed as ovarian cancer awareness month. It is the third most common cancer in women worldwide and nearly 20,000 women are newly diagnosed every year worldwide.
Others have found that DOT1L is overexpressed in several cancer types, and recent clinical work has shown synergistic ant proliferative activity for a DOT1L inhibitor against MLL-rearranged leukaemia.